

# T. ROWE PRICE FUNDS SICAV

Société d'investissement à capital variable  
Registered office: European Bank & Business Center,  
6c route de Trèves,  
L-2633 Senningerberg,  
Grand Duchy of Luxembourg



**IMPORTANT: This letter is important and requires your immediate attention. If you have any questions about the content of this letter, you should seek independent professional advice. The directors of the Company accept full responsibility for the accuracy of the information contained in this letter and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts, the omission of which would make any statement misleading.**

10 April 2026

All capitalized terms used in this letter and not otherwise defined herein shall have the meanings ascribed to them in the existing Hong Kong Offering Document (comprising the Prospectus, Hong Kong Covering Document and Product Key Facts Statements (“KFS”) of the Authorised Sub-Funds).

## **Re.: Important Notice: Merger of the Asian Opportunities Equity Fund (the “Merging Sub-Fund”) into the Asian ex-Japan Equity Fund (the “Receiving Sub-Fund”)**

Dear Hong Kong Shareholder,

We are writing to inform you of the decision of the board of directors (the “Board”) of T. Rowe Price Funds SICAV (the “Company”) that on 12 June 2026 (the “Merger Date”) the Merging Sub-Fund will merge into the Receiving Sub-Fund in which you own shares.

### **1. Reason for the Merger**

The proposed merger of the Merging Sub-Fund into the Receiving Sub-Fund (the “Merger”) is intended to deliver efficiencies which will contribute to improved outcomes for investors by consolidating two funds with closely aligned investment objectives, risk profiles and asset allocations into a single, larger fund. The Merger aims to (i) enhance the fund’s potential to grow further and achieve efficiencies of scale, and to (ii) streamline the available product range.

Since the Merging and Receiving Sub-Funds have very similar investment universe and features, investors are not expected to experience any disruption in terms of investment strategy, risk profile, or management approach.

### **2. Impact and Merger Process**

The Merger will not have any negative effect on the value, costs, or performance of your investment in the Receiving Sub-Fund.

On the Merger Date, the assets and liabilities of the Merging Sub-Fund will be transferred into the Receiving Sub-Fund. The Merger will increase the assets under management of the Receiving Sub-Fund.

No legal, advisory or administrative costs associated with the Merger will be borne by the Receiving Sub-Fund. When the Merger occurs, all the assets and liabilities of the Merging Sub-Fund will be transferred to the Receiving Sub-Fund, and the Merging Sub-Fund will cease to exist.

Subscriptions, switches and redemptions in the Receiving Sub-Fund will not be suspended to carry out the Merger.

### 3. **Your options**

You do not need to take any action. However, if, as a consequence of the Merger, you wish to transfer your investment to another Authorised Sub-Fund of the Company that are authorised by the SFC pursuant to section 104 of the SFO<sup>1</sup> or redeem your shares holding in the Receiving Sub-Fund, you may do so at any time as per the conditions set in the Hong Kong Offering Document and free of charge, by sending dealing instructions before 5 June 2026 at 20:00 Hong Kong time (cut-off time).

### 4. **Additional Information**

Additional information, including the auditor's merger report, Hong Kong Offering Document and most recent financial reports of the Company are available at <https://www.troweprice.com/en/hk/home> or from the Hong Kong Representative's office at 6/F, Chater House, 8 Connaught Road Central, Hong Kong during normal business hours. Please note that this website has not been reviewed by the SFC and may contain information of funds not authorised by the SFC.

**The Board further recommends that you inform yourself of, and where appropriate take advice on, the tax and investment consequences of the foregoing in your country of citizenship, residence or domicile.**

Thank you for the continued trust and confidence that you have placed in T. Rowe Price. Should you have any queries in relation to the above, please do not hesitate to contact the Hong Kong Representative at 6/F, Chater House, 8 Connaught Road Central, Hong Kong (+852 2536 7800).

Yours faithfully,

The Board of Directors

<sup>1</sup> SFC authorization is not a recommendation or endorsement of a fund nor does it guarantee the commercial merits of the fund or its performance. It does not mean the fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.



## 普徠仕（盧森堡）系列

資本可變投資公司(Société d'investissement à capital variable)  
註冊辦事處：European Bank & Business Center,  
6c route de Trèves,  
L-2633 Senningerberg,  
Grand Duchy of Luxembourg

**重要提示：本函件乃重要文件，務須閣下即時垂注。如閣下對本函件的内容有任何疑問，應尋求獨立專業意見。本公司的董事願對本函件所載資料的準確性承擔全部責任，並在作出一切合理查詢後確認，盡彼等所知及所信，並無遺漏其他事實以致本函件中任何陳述有誤導成分。**

本函件所用及文內未有另行定義的所有詞語具有現有香港銷售文件（包括公開說明書、香港說明文件及認可附屬基金的产品資料概要（「**產品資料概要**」））賦予該詞的涵義。

**關於：重要通告：亞洲機遇股票基金（「**合併附屬基金**」）併入亞洲（日本除外）股票基金（「**接收附屬基金**」）**

親愛的香港股東：

我們謹此致函通知閣下，普徠仕（盧森堡）系列（「**本公司**」）董事會（「**董事會**」）已決定，於2026年6月12日（「**合併日期**」）合併附屬基金將併入閣下持股的接收附屬基金。

### 1. 合併的理由

將合併附屬基金併入接收附屬基金的擬議合併（「**合併**」）透過將投資目標、風險狀況及資產配置均高度一致的兩個基金合併為規模更大的單一基金，從而提高效率，繼而改善投資者的投資成果。合併旨在(i)提升基金進一步增長的潛力並實現規模效益，及(ii)精簡現有產品系列。

由於合併與接收附屬基金的投資範圍及特點非常相似，預計投資者在投資策略、風險狀況或管理方法方面將不會受到任何干擾。

### 2. 影響及合併流程

合併將不會對閣下在接收附屬基金中的投資價值、成本或表現產生任何負面影響。

於合併日期，合併附屬基金的資產及負債將轉移至接收附屬基金。合併將增加接收附屬基金的資產管理規模。

接收附屬基金將不會承擔與合併相關的任何法律、諮詢或行政費用。當合併發生時，合併附屬基金的所有資產及負債將轉移至接收附屬基金，合併附屬基金將不再存在。

接收附屬基金的認購、轉換及贖回將不會因合併而暫停。

### 3. 閣下的選擇

閣下無需採取任何行動。然而，如因應合併，閣下希望將投資轉換至本公司另一個根據《證券及期貨條例》第104條獲證監會認可的認可附屬基金<sup>1</sup>或贖回閣下於接收附屬基金持有的股份，閣下可按照香港銷售文件所載的條件，於2026年6月5日20:00時（香港時間）（截止時間）前發送交易指令，隨時免費進行。

#### 4. 額外資料

額外資料 (包括核數師合併報告、香港銷售文件及本公司的最近期財務報告) 可於<https://www.troweprice.com/en/hk/home>，或在正常辦公時間內於香港代表辦事處 (地址為香港中環干諾道中8號遮打大廈6樓) 查閱。請注意，本網站並未經證監會審閱，故可能載有未經證監會認可的基金資料。

**董事會進一步建議閣下了解上述事項於閣下的公民身份、居住地或住所所在國家的稅務及投資影響，並於適當情況下徵詢意見。**

感謝閣下一直以來對普徠仕的信賴和信任。閣下如對上文有任何疑問，請隨時聯絡香港代表，地址為香港中環干諾道中8號遮打大廈6樓 (電話：+852 2536 7800)。

董事會

謹啟

2026年4月10日

<sup>1</sup> 證監會認可並不同推薦或認許有關基金，亦非對該基金的商業價值或其表現作出保證，更不代表該基金適合所有投資者，或認許該基金適合任何特定投資者或投資者類別。